We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

OvaScience Board Ducks Shareholders' IVF Treatment Suit

Law360, Boston (April 16, 2018, 3:16 PM EDT) -- The board of OvaScience Inc. on Friday escaped a derivative suit brought by shareholders who claim that misleading statements about an in vitro fertilization treatment caused a sharp stock drop, after a federal judge ruled the biotech company did not make any transactions requiring shareholder approval.

The Waltham, Massachusetts-based fertility treatment developer overpromised on the number of patients for its pricey IVF product called Augment and oversold its success rate, according to the shareholders' complaint. When OvaScience later reported that it would not meet its goal, the...
To view the full article, register now.




Case Information

Case Title

Chiu et al v. Dipp et al

Case Number




Nature of Suit



Indira Talwani

Date Filed

July 27, 2017

Law Firms


Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.